(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 3.28% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.01%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.06%.
Zymeworks's revenue in 2026 is $265,973,000.On average, 13 Wall Street analysts forecast ZYME's revenue for 2026 to be $21,556,213,879, with the lowest ZYME revenue forecast at $18,380,802,093, and the highest ZYME revenue forecast at $25,855,445,314. On average, 12 Wall Street analysts forecast ZYME's revenue for 2027 to be $24,674,330,191, with the lowest ZYME revenue forecast at $10,350,461,809, and the highest ZYME revenue forecast at $34,986,825,120.
In 2028, ZYME is forecast to generate $20,224,611,849 in revenue, with the lowest revenue forecast at $4,532,555,171 and the highest revenue forecast at $37,328,346,158.